Pilot study: Noninvasive monitoring of oral flecainide's effects on atrial electrophysiology during persistent human atrial fibrillation using the surface electrocardiogram

Annals of Noninvasive Electrocardiology

Volumn 10, Issue 2, 2005, Pages 206-210

  Husser, Daniela ^a   Binias, Karl Heinz ^a   Stridh, Martin ^b   Sornmo, Leif ^b   Olsson, S Bertil ^b   Molling, Jochen ^a   Geller, Christoph ^a   Klein, Helmut U ^a   Bollmann, Andreas ^a,c  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Atrial fibrillation; Drug monitoring; ECG signal processing; Flecainide

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; FLECAINIDE ACETATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG STABILITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART SIZE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAINTENANCE THERAPY; MALE; NON INVASIVE MEASUREMENT; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; FLECAINIDE; HEART ATRIA; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; PILOT PROJECTS;

EID: 18444405841     PISSN: 1082720X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2005.05616.x     Document Type: Article

References (15)

1. Boriani G, Capucci A, Strocchi E, et al. Flecainide acetate: Concentration-response relationships for antiarrhythmic and electrocardiographic effects. Int J Clin Pharmacol Res 1993;13:211-219.
2. Padrini R, Piovan D, Busa M, et al. Pharmacodynamic variability of flecainide assessed by QRS changes. Clin Pharmacol Ther 1993;53:59-64.
3. Wang Z, Page P, Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res 1992;71:271-287.
4. Wijffels MC, Dorland R, Mast F, et al. Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: Effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation 2000;102:260-267.
5. Biffi M, Boriani G, Bronzetti G, et al. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. Heart 1999;82:176-182.
6. Bollmann A, Kanuru NK, McTeague KK, et al. Frequency analysis of human atrial fibrillation using the surface electrocardiogram and its response to ibutilide. Am J Cardiol 1998;81:1439-1445.
7. Holm M, Pehrson S, Ingemansson M, et al. Non-invasive assessment of the atrial cycle length during atrial fibrillation in man: Introducing, validating and illustrating a new ECG method. Cardiovasc Res 1998;38:69-81.
8. Bollmann A, Sonne K, Esperer HD, et al. Non-invasive assessment of fibrillatory activity in patients with paroxysmal and persistent atrial fibrillation using the Holter ECG. Cardiovasc Res 1999;44:60-66.
9. Bollmann A, Binias KH, Toepffer I, et al. Importance of left atrial diameter and atrial fibrillatory frequency for conversion of persistent atrial fibrillation with oral flecainide. Am J Cardiol 2002;90:1011-1014.
10. Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases. Eur Heart J 2001;22:1162-1182.
11. Bollmann A, Husser D, Stridh M, et al. Frequency measures obtained from the surface electrocardiogram in atrial fibrillation research and clinical decision-making. J Cardiovasc Electrophysiol 2003;14:S154-S161.
12. Goy JJ, Kaufmann U, Kappenberger L, et al. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol 1988;62:38D-40D.
13. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
14. Gillis AM, Duff HJ, Mitchell LB, et al. Myocardial uptake and pharmacodynamics of procainamide in patients with coronary heart disease and sustained ventricular tachyarrhythmias. J Pharmacol Exp Ther 1993;266:1001-1006.
15. Candinas R, Frielingsdorf J, Ha HR, et al. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur J Clin Pharmacol 1998;53:331-336.